Aardvark Therapeutics Inc (AARD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2024 | 09-2024 | 06-2024 | 03-2024 | 12-2023 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -20,588 | -11,809 | -7,627 | -2,178 | -7,208 |
| Depreciation Amortization | -80 | 8 | N/A | 2 | 97 |
| Accounts payable and accrued liabilities | 798 | -395 | 189 | -445 | N/A |
| Other Working Capital | 1,573 | 758 | 854 | -319 | -81 |
| Other Operating Activity | 210 | 1,078 | 179 | 750 | 1,368 |
| Operating Cash Flow | $-18,087 | $-10,360 | $-6,405 | $-2,190 | $-5,824 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -11,889 | N/A | N/A | N/A | N/A |
| PPE Investments | -109 | -103 | -98 | -5 | 0 |
| Investing Cash Flow | $-11,998 | $-103 | $-98 | $-5 | $0 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 332 | 169 | N/A | N/A | N/A |
| Other Financing Activity | 81,659 | 82,836 | 82,941 | 0 | 0 |
| Financing Cash Flow | $81,991 | $83,005 | $82,941 | $N/A | $0 |
| Beginning Cash Position | 9,735 | 9,735 | 9,735 | 9,735 | 15,559 |
| End Cash Position | 61,641 | 82,277 | 86,173 | 7,540 | 9,735 |
| Net Cash Flow | $51,906 | $72,542 | $76,438 | $-2,195 | $-5,824 |
| Free Cash Flow | |||||
| Operating Cash Flow | -18,087 | -10,360 | -6,405 | -2,190 | -5,824 |
| Capital Expenditure | -109 | -103 | -98 | -5 | N/A |
| Free Cash Flow | -18,196 | -10,463 | -6,503 | -2,195 | -5,824 |